From Nasdaq: 2025-04-29 08:45:00

Palatin Technologies, Inc. shared updated results from its Phase 3 study on PL9643 for dry eye disease. The study showed higher symptom resolution with PL9643 compared to placebo in 6 out of 13 symptoms. Patients also experienced early and sustained symptom relief. CEO Carl Spana highlighted PL9643’s potential as a top-tier treatment. These results meet FDA approval criteria for symptom improvement.



Read more at Nasdaq: Palatin Reports Positive Results From Responder Analyses Of Phase 3 MELODY-1 Study In DED